Glutathione Reconstitution Calculator

Glutathione is not approved by the U.S. FDA as a prescription drug for most indications. It is sold as an oral dietary supplement and used as a compounded injectable in practitioner settings (community protocol). Regulatory status varies internationally.

Oral GSH has poor plasma bioavailability; in a human crossover RCT, sublingual GSH significantly raised total/reduced plasma GSH and the GSH/GSSG ratio compared with oral GSH, and improved plasma vitamin E after 3 weeks. Injectable routes bypass first-pass degradation and likely produce higher exposure, but direct head-to-head human pharmacokinetic trials are lacking (community protocol). For high-dose clinical use, intramuscular, subcutaneous, or IV routes are typical; for daily maintenance, sublingual or liposomal oral forms are more practical.

There is no FDA-approved injectable dose. Common practitioner protocols use 100–200 mg intramuscular or subcutaneous 2–3 times weekly, or 600–1200 mg IV once weekly for 4–8 weeks, followed by tapered maintenance at 1–2 times monthly (community protocol). Oral/liposomal protocols often use 250–500 mg/day; sublingual glutathione is commonly used in the range of 100–400 mg/day (community protocol).

No adequate human pregnancy or lactation safety data exist for supplemental or injectable glutathione. Endogenous GSH is essential for cellular redox balance and transport, but pharmacological dosing has not been tested for reproductive safety. Avoid use during pregnancy and lactation unless under direct specialist care and with explicit risk/benefit assessment (community protocol).

No long-term RCTs define a maximum duration. GSH synthesis and cellular uptake are tightly autoregulated, but tissue GSH levels decline with aging and chronic disease. In the absence of long-term safety data, practitioner consensus commonly cycles injectable GSH 8–12 weeks on, 2–4 weeks off, or uses a loading phase followed by maintenance 1–2 times monthly (community protocol).

In the only direct human crossover RCT, sublingual GSH produced greater increases in total/reduced plasma GSH and the GSH/GSSG ratio than oral GSH or NAC. γ-Glutamylcysteine (GGC) bypasses the rate-limiting glutamate cysteine ligase step; in human astrocyte cultures it restored GSH and increased antioxidant enzymes, and in a mouse sepsis model it showed stronger anti-inflammatory effect than NAC or GSH. NAC has the largest human safety record; GSH offers direct administration; GGC is promising but least tested in humans (community protocol).

Compounded injectable GSH should be refrigerated at 2–8°C, protected from light, and used promptly after reconstitution because reduced GSH is oxidation-sensitive. Oral and sublingual forms should be stored cool and dry. For travel, use an insulated cooler with cold packs (community protocol).